[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-promyelocytic-leukemia-apl\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-promyelocytic-leukemia-apl":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,87,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100638742","phase-2-lisaftoclax-for-prevention-of-differentiation-syndrom-in-acute-promyelocytic-leukemia-patients-100638742",false,"NCT07597941","Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients","Lisaftoclax for Prevention of Differentiation Syndrom (DS) in Acute Promyelocytic Leukemia (APL) Patients : An Open-lable, Single-arm, Multicenter, Phase Ⅱ Clinical Trail","Inclusion Criteria:\n\n* 1\\. Patients aged ≥ 16 years old.\n* 2\\. Confirmed diagnosis of acute promyelocytic leukemia (APL) by morphology, flow cytometry, and cytogenetics\u002Fmolecular testing.\n* 3\\. ECOG performance status 0-2.\n* 4\\. Adequate organ function:\n* Serum creatinine ≤ 1.5 × ULN\n* Total bilirubin ≤ 2 × ULN\n* AST\u002FALT ≤ 3 × ULN\n* 5\\. Able to understand and sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Concurrent participation in another interventional clinical trial.\n* 2\\. History of other malignancies within the past 5 years (except cured basal cell carcinoma or in situ cervical cancer).\n* 3\\. Severe uncontrolled infection or other serious underlying diseases that may interfere with study treatment or follow-up.\n* 4\\. Known hypersensitivity to lisaftoclax, ATRA, ATO, or any components of the study regimen.\n* 5\\. Pregnant or breastfeeding women.","ALL","16 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","This study is to assess the efficacy and safety of Lisaftoclax for prevention of DS in APL patients undergoing ATRA\u002FATO induction regimen.",[27],"Acute Promyelocytic Leukemia (APL)",[29,30,31],"Acute Promyelocytic Leukemia","Lisaftoclax","Differentiation Syndrom","NOT_YET_RECRUITING","2026-06-26",{"date":35,"type":36},"2026-06-30","ACTUAL",{"date":38,"type":20},"2026-07",{"date":40,"type":20},"2028-12",{"name":42,"class":43},"The Affiliated People's Hospital of Ningbo University","OTHER_GOV",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100631728","phase-3-pivotal-open-label-phase-3-clinical-study-of-qtx-2101-in-adult-patients-with-acute-promyelocytic-leukemia-100631728","NCT07504458","Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia","A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia","QUATRO-APL","Inclusion Criteria:\n\n1. Informed Consent\n2. Participants must be between 18 and under 71 years of age\n3. Participants must have a confirmed diagnosis of APL proven by standard genetic testing (t(15;17) or PML-RARA)\n4. Participants must be classified as low- or intermediate-risk APL\n5. Participants must be willing and able to comply with the scheduled study visits, treatment plans, laboratory tests, contraception guidance, and other procedures\n\nExclusion Criteria\n\n1. Participants who have significant heart rhythm problems including long QT syndrome, serious arrhythmias, very slow heart rate, or prolonged QTc on ECG\n2. Participants who have central nervous system leukemia\n3. Participants having serious ongoing medical conditions or infections including uncontrolled infections, severe organ disease, or conditions that make study participation unsafe\n4. Participants who are pregnant, breastfeeding, or unwilling to use contraception\n5. Participants who are unable to safely take study medication, including severe neuropathy, inability to swallow oral medication, malabsorption issues, or known allergy to ATO or ATRA","18 Years","71 Years",{"count":55,"type":20},150,[24],"This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.",[27,59,60,61,29],"Acute Promyelocytic Leukaemia","Acute Promyelocytic Leukemia With PML-RARA","Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA",[63,29,64,65,66,67,68,69,70,71,72,73,74],"APL","Hematology","Oncology","Leukemia","Hematologic Disease","Drug Therapy","Therapeutics","Blood Cancer","Heme Malignancy","Arsenic","low-risk APL","standard-risk APL","RECRUITING","2026-06-13",{"date":78,"type":36},"2026-06-16",{"date":80,"type":36},"2026-06-08",{"date":82,"type":20},"2030-12",{"name":84,"class":85},"Quetzal Therapeutics","INDUSTRY",7,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":95,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":21,"phases":98,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":4},"100615733","phase-3-a-trial-to-investigate-whether-oral-arsenic-trioxide-is-similar-to-intravenous-arsenic-trioxide-in-pharmacokinetics-safety-and-efficacy-latitudesdkars-301-100615733","NCT07296445","A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE\u002FSDKARS-301)","LATITUDE - A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2-Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-High-Risk, Acute Promyelocytic Leukemia","LATITUDE","Key Inclusion Criteria:\n\n* Participants must have diagnosis of newly diagnosed non-high risk APL with a WBC count at diagnosis ≤ 10,000 cells\u002FµL, completed induction with ATO\u002FATRA and achieved morphologic CR with hematologic recovery\n* Eastern Cooperative Oncology Group performance status ≤2\n* Adequate liver, kidney, and cardiac function\n* Have a life expectancy of at least 9 months\n* Negative serum pregnancy test\n\nKey Exclusion Criteria:\n\n* Diagnosis of relapsed or refractory APL.\n* Fridericia's corrected QT interval (QTcF) \\>450 milliseconds (males) and \\>460 milliseconds (females)\n* Any gastrointestinal (GI) issue likely to affect oral drug absorption\u002Fmetabolism or inability to swallow oral medication\n* Prior malignancy or currently receiving treatment for a non-APL malignancy, with the following exceptions: basal cell or squamous cell skin cancer treated with surgical resection, in situ cervical cancer, localized prostate cancer or breast cancer treated with hormone therapy or surgical resection, or other cancer from which the participant has been disease free for at least 2 years.\n* Pregnant or nursing females or is of reproductive potential and unwilling to comply with contraceptive requirements.\n* Participant has known active or chronic hepatitis B or active hepatitis C (HCV) infection or human immunodeficiency virus (HIV)-positive with detectable viral load.\n\nNote: Additional inclusion\u002Fexclusion criteria may apply, per protocol.","12 Years",{"count":97,"type":20},120,[24],"LATITUDE: A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2- Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-High Risk, Acute Promyelocytic Leukemia\n\nRationale:\n\nSDK Therapeutics is developing an oral formulation of arsenic trioxide (ATO) for the treatment of acute promyelocytic leukemia (APL). Patients with APL are usually treated with arsenic trioxide (ATO) through an IV along with all-trans retinoic acid (ATRA) taken by mouth. Receiving ATO through an IV requires patients with APL to go to the hospital a lot and get long treatments (sometimes every day over a year of treatment). This can be hard and uncomfortable. If ATO can be taken by mouth, it would be much easier for patients and their families.\n\nObjective:\n\nThe main objective is to show that the body absorbs the same amount of ATO whether it's taken by mouth or through an IV. Other objectives include checking if ATO taken by mouth works just as well, causes fewer heart problems, is safe, and improves quality of life compared with ATO given through an IV.\n\nMain trial endpoints:\n\nThe main endpoint being measured is how much ATO is in the blood after 5 doses. Another important endpoint is how many patients have no signs of cancer in their blood after 3 rounds of treatment.\n\nSecondary trial endpoints:\n\nOther things being measured include: whether patients stay cancer-free over 2 years; changes in heart rhythm; side effects and lab test results; how patients feel during treatment; how much of ATO is in the blood; and how often patients feel bothered by side effects.\n\nTrial design:\n\nThis is an open-label study, meaning everyone knows which treatment they are getting. Patients will get 4 rounds of treatment, each lasting 8 weeks. After that, patients will have check-ups every 3 months to assess safety and disease status for a total of 2 years.\n\nTrial population:\n\nThe study includes adults and teens (12 years and older) who have APL, are not high-risk, and have already finished the first part of their treatment (induction) with IV ATO and ATRA.\n\nInterventions:\n\nThere are 3 groups in the study:\n\nCohort A: Takes 0.15 mg\u002Fkg Oral ATO for 3 rounds, then switches to 0.15 mg\u002Fkg IV ATO for part of the 4th round.\n\nCohort B: Takes 0.15 mg\u002Fkg IV ATO for 3 rounds, then switches to 0.15 mg\u002Fkg Oral ATO for part of the 4th round.\n\nCohort C: Takes 0.15 mg\u002Fkg Oral ATO for all 4 rounds.\n\nAll cohorts also take 45 mg\u002Fm2\u002Fday ATRA during certain weeks of each round. Doctors will assess efficacy by checking bone marrow samples before and during treatment to see if the cancer is gone. Special lab tests will be used to look for cancer cells. Safety will be assessed by checking for side effects using blood tests, heart tests, physical exams, and other health checks. Quality of life will be assessed by the patients who will fill out surveys about how they feel during treatment and how much the side effects bother them. The study will also look at how often patients need to go to the doctor or hospital; how treatment affects daily life and work; and how satisfied patients are with their treatment.",[27,59,60,61,63,29,101,102,103],"Leukaemia","Leukemia Acute Promyelocytic Leukemia (APL)","Leukemia, Acute",[105,106],"Oral Arsenic Trioxide","Oral ATO","2025-12-25",{"date":109,"type":36},"2025-12-29",{"date":111,"type":20},"2026-01",{"date":113,"type":20},"2029-01",{"name":115,"class":85},"SDK Therapeutics, Inc.",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":130,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":145},"100591580","phase-2-oral-arsenic-with-atra-for-newly-diagnosed-patients-with-acute-promyelocytic-leukemia-100591580","NCT06982274","Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia","Combination of Oral Arsenic With ATRA and Minimal-Dose Chemotherapy for Newly Diagnosed Patients With Acute Promyelocytic Leukemia: a Study by the International Consortium on APL","IC-APL2020","Inclusion Criteria:\n\n* Informed consent\n* New diagnosis of APL by cytomorphology, confirmed for molecular analysis\n* Age ≥18 and ≤75 years\n* Serum total bilirubin ≤ 3.0 mg\u002Fdl (≤ 51 μmol\u002Fl)\n* Serum creatinine ≤ 3.0 mg\u002Fdl (≤ 260 μmol\u002Fl)\n* Women must meet at least one of the following criteria to be eligible for inclusion in the study: Postmenopausal (12 months of amenorrhea or 6 months of amenorrhea with serum FSH \\> 40 U\u002Fml); After undergoing hysterectomy or bilateral oophorectomy; Continuous and correct use of a contraceptive method with a Pearl Index \\\u003C1% (e.g., implants, oral contraceptives, intrauterine devices); Sexual abstinence; Vasectomy of sexual partner.\n\nExclusion Criteria:\n\n* High-risk patients who are not eligible for chemotherapy according to the judgment of the treating physician;\n* Age \\\u003C18 or \\>75 years\n* Other active malignancy at the time of study entry\n* Lack of diagnostic confirmation at the genetic level\n* Significant arrhythmias, ECG abnormalities, or neuropathy: Congenital long QT syndrome; History or presence of significant ventricular or atrial tachyarrhythmia; Clinically significant resting bradycardia (\\\u003C50 beats per minute); QTc \\> 500 ms on ECG screening for both sexes; Right bundle branch block with left anterior hemiblock or bifascicular block\n* High-risk patients with other cardiac contraindications for intensive chemotherapy (LVEF \\\u003C 50%)\n* Uncontrolled and potentially fatal infections\n* Severe uncontrolled pulmonary or cardiac disease\n* Severe hepatic or renal dysfunction\n* Known HIV and\u002For hepatitis C infection\n* Pregnant or breastfeeding women\n* Allergy to the study drug or excipients in the study medication\n* Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or the assessment of study outcomes\n* Use of other investigational drugs at the time of enrollment or within 30 days before study entry.","75 Years",{"count":126,"type":20},115,[23],"It is a non-randomized, multicenter, prospective study, aiming to treat patients with newly diagnosed acute promyelocytic leukemia with a combination of oral arsenic and atra, with low dose chemotherapy for those with high-risk disease (white blood cell count above 10x10a9\u002FL). The primary objective is to assess the 2-year overall survival (OS) in these patients, comparing with the historical control group of patients treated with ATRA\u002Fchemotherapy according to the IC-APL 2006 protocol.",[27],[131,132,133,134],"Acute promyelocytic leukemia","Oral arsenic","Survival","All trans-retinoic acid","2025-05-26",{"date":137,"type":36},"2025-05-30",{"date":139,"type":36},"2023-10-20",{"date":141,"type":20},"2029-11",{"name":143,"class":144},"Instituto do Cancer do Estado de São Paulo","OTHER",1]